We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 22 for:    Facebook AND COVID | NIH, Other
Previous Study | Return to List | Next Study

Discussing COVID-19 Vaccines in Private Facebook Groups

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05422898
Recruitment Status : Completed
First Posted : June 21, 2022
Last Update Posted : June 21, 2022
Information provided by (Responsible Party):
George Washington University

Brief Summary:
As the COVID-19 pandemic persists, a sizable proportion of the U.S. population remains unvaccinated and at high risk of death and serious illness from COVID-19. Vaccine hesitancy, fueled by the proliferation of vaccine misinformation on social media, is one factor contributing to lack of vaccination. Current attempts to overcome vaccine misinformation focus on correcting or debunking falsehoods. Although debunking strategies are important components to any public health campaign, communications must also address rationales for vaccine hesitancy that vary among individuals and communities, and directly address the gist of their concerns in an empathetic, non-judgmental manner. We will conduct a randomized controlled trial to test the effectiveness of empathic, relationship-building interactions relative to standard provision of information on social media to address COVID-19 vaccine hesitancy.

Condition or disease Intervention/treatment Phase
COVID-19 Behavioral: Gist messages on COVID-19 vaccination Behavioral: COVID-19 vaccine information Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 508 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Empathic Engagement With the COVID-19 Vaccine Hesitant in Private Facebook Groups
Actual Study Start Date : January 17, 2022
Actual Primary Completion Date : April 4, 2022
Actual Study Completion Date : April 4, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Gist
Gist-based messages on COVID-19 vaccination and moderated group discussions in a private Facebook group
Behavioral: Gist messages on COVID-19 vaccination
Participants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator

Placebo Comparator: Information
Link to Facebook COVID-19 Information Center
Behavioral: COVID-19 vaccine information
Participants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group

Primary Outcome Measures :
  1. Engagement and satisfaction with the program [ Time Frame: 4 weeks ]
    Engagement includes participation in the Facebook group; satisfaction=self-rated overall satisfaction with the program (7-point scale)

Secondary Outcome Measures :
  1. Proportion of participants getting the COVID-19 vaccine [ Time Frame: 4 weeks ]
    self-reported vaccination status

  2. Change in COVID-19 vaccination intention [ Time Frame: 4 weeks ]
    Self-reported intention to get the COVID-19 vaccine (7-point scale)

  3. Change in intention to encourage others to get the COVID-19 vaccine [ Time Frame: 4 weeks ]
    Self-reported intention to encourage others to get the COVID-19 vaccine (7-point scale)

  4. Change in COVID-19 vaccine confidence [ Time Frame: 4 weeks ]
    Self-reported confidence in the COVID-19 vaccine (5-point scale)

  5. Change in general vaccine confidence [ Time Frame: 4 weeks ]
    Self-reported confidence in vaccines (7-point scale)

  6. Change in vaccine hesitancy [ Time Frame: 4 weeks ]
    Self-reported vaccine hesitancy (7-point scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • reside in the U.S.
  • unvaccinated from COVID-19
  • Use Facebook regularly (at least 1/day)

Exclusion Criteria:

  • age <18 years
  • do not reside in the U.S.
  • vaccinated from COVID-19
  • do not use Facebook regularly (at least 1/day)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05422898

Layout table for location information
United States, District of Columbia
George Washington University
Washington, District of Columbia, United States, 20052
Sponsors and Collaborators
George Washington University
Layout table for additonal information
Responsible Party: George Washington University
ClinicalTrials.gov Identifier: NCT05422898    
Other Study ID Numbers: NCR213861
First Posted: June 21, 2022    Key Record Dates
Last Update Posted: June 21, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by George Washington University:
vaccine hesitancy
social media
health behavior
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Viral
Respiratory Tract Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases